Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017136
Chunk: 92

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 92
---
 or any other theory), including any claim under the U.S. federal securities
laws.

If we or the depositary were to oppose
a jury trial demand based on such waiver, the court would determine whether the waiver was enforceable in the facts and circumstances
of that case in accordance with applicable state and federal law, including whether a party knowingly, intelligently and voluntarily waived
the right to a jury trial. The waiver to right to a jury trial in the Deposit Agreement is not intended to be deemed a waiver by any holder
or beneficial owner of our or the depositary’s compliance with the U.S. federal securities laws and the rules and regulations promulgated
thereunder.

| 49 |

<div align='center'>PLAN OF DISTRIBUTION</div>

Each selling shareholder and any of their
pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their Ordinary Shares represented by Depositary
Shares covered by this prospectus on the principal trading market or any other stock exchange, market or trading facility on which the
securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A selling shareholder may use any
one or more of the following methods when selling securities:

| · | ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; |

| · | block trades in which the broker-dealer will attempt to sell the securities as agent but may position 
 and resell a portion of the block as principal to facilitate the transaction;                         |

| · | purchases by a broker-dealer as principal and resale by the broker-dealer for its account; |

| · | an exchange distribution in accordance with the rules of the applicable exchange; |

| · | privately negotiated transactions; |

| · | settlement of short sales; |

| · | in transactions through broker-dealers that agree with the selling shareholders to sell a specified number 
 of such securities at a stipulated price per security;                                                     |

| · | through the writing or settlement of options or other hedging transactions, whether through an options 
 exchange or otherwise;                                                                                 |

| · | a combination of any such methods of sale; or |

| · | any other method permitted pursuant to applicable law. |

The selling shareholders may also sell
securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.

Broker-dealers engaged by the selling shareholders
may arrange for other brokers-dealers to participate in